Prescribers remain cautious about substituting generic drugs for narrow therapeutic index (NTI) medications due to risks of therapeutic failure or toxicity. Despite FDA assurances, many doctors prefer brand-name NTI drugs for stability, especially with warfarin, levothyroxine, and tacrolimus. State laws, communication gaps, and real-world errors fuel ongoing debate.